임상시험 이미징 시장 규모, 점유율, 동향 분석 보고서 : 모달리티별, 치료 분야별, 서비스별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Clinical Trial Imaging Market Size, Share & Trends Analysis Report By Modality (Computed Tomography Scan, Magnetic Resonance Imaging), By Therapeutic Area, By Services, By End Use, Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,675,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,133,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 13,049,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

임상시험 이미징 시장 성장과 동향:

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 임상시험 이미징 시장 규모는 2025년부터 2030년까지 연평균 7.8%의 CAGR을 기록하여 2030년에는 19억 1,000만 달러에 달할 것으로 예상됩니다.

만성질환을 치료할 수 있는 새로운 약물과 치료법을 발견하기 위한 연구개발비 증가로 업계가 성장하고 있습니다. 체내 검사에서 얻은 이미지는 약물 활성을 판단하는 데 사용됩니다. 임상시험용 이미징은 신속하고 상세하며 정확한 스크리닝을 제공합니다. 임상시험 영상 진단에 대한 요구는 임상시험의 모든 단계에서 빠르게 증가하고 있습니다. 임상시험에서 의료 이미지는 주요, 정량적, 대체 바이오마커로 사용됩니다.

임상시험 설계에는 환자군 선정, 바이오마커에 기반한 계층화, 치료군 배정을 위한 다양한 방법, 효율적이고 신뢰할 수 있는 평가변수 선택 및 대체 평가변수 검증, 표본 크기 계산, 시험 시뮬레이션, 적응증 시험 설정, 통계 분석, 중간 분석, EMA, FDA 등 규제 당국과 시험 설계에 대해 논의하고 시험 결과를 방어하기 위한 고객 대응 지원 등이 포함됩니다.

시장의 기업들은 임상 개발 강화를 위한 분석 시험 서비스, 약동학, 판독, 약력학 서비스를 제공하고 있으며, IXICO는 신경과학 임상시험을 촉진하는 첨단 기술을 제공하고 있습니다. 이 회사의 이미징 바이오마커는 신경 영상에 사용되는 치료법의 안전성과 효능을 측정하는 데 도움이 됩니다. 이미징 바이오마커는 방사선학적 판독에 효과적입니다. 이를 통해 중추신경용 MRI 스캔을 판독할 수 있으며, 약물의 안전성과 피험자 적격성에 대한 지속적인 모니터링 평가를 강화할 수 있습니다.

임상시험 이미징 시장 보고서 하이라이트

• 판독 및 분석 서비스 부문은 2024년 30.95%로 가장 큰 시장 점유율을 차지했으며, 2025년부터 2030년까지 CAGR 8.4%로 성장할 것으로 예상되며, 임상 연구에서 영상 데이터의 정확성과 신뢰성을 보장하는 데 중요한 역할을 할 것으로 강조되고 있습니다.
• 생명공학 및 제약 회사 부문은 2024년 28.7%의 가장 큰 점유율을 차지했습니다. 이 부문의 우위 요인은 만성질환을 치료하기위한 새로운 약물 및 치료법 개발의 필요성입니다.
• 종양학 부문은 2024년 23.63%의 가장 큰 점유율을 차지했습니다. 암 환자의 높은 유병률과 다양한 유형의 암을 치료하기 위한 새롭고 혁신적인 치료법에 대한 끊임없는 요구가 시장 성장을 촉진할 것으로 예상됩니다.
• CRO(임상시험수탁기관) 분야는 만성질환에 대한 신약 및 치료제 개발에 필수적인 역할을 담당하고 있어 예측기간 동안 8.5%의 CAGR로 큰 폭의 성장이 예상됩니다.
• 북미는 노인 인구 증가, 만성질환 및 치료 옵션에 대한 수요 증가로 인해 2024년 매출 점유율 47.93%를 차지하며 시장을 주도했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 임상시험 이미징 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상부 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 임상시험 이미징 시장 분석 툴
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석

제4장 임상시험 이미징 시장 : 모달리티별 추정·동향 분석

• 부문 대시보드
• 임상시험 이미징 시장 : 모달리티 변동 분석
• 임상시험 이미징 시장 모달리티별 전망
• 2018년부터 2030년까지 시장 규모와 예측 및 동향 분석
• 컴퓨터 단층촬영 스캔
• 자기공명영상
• X선
• 초음파
• 광간섭단층촬영(OCT)
• 기타 모달리티

제5장 임상시험 이미징 시장 : 치료 분야별 추정·동향 분석

• 부문 대시보드
• 임상시험 이미징 시장 : 치료 분야 변동 분석
• 임상시험 이미징 시장 치료 분야 전망
• 2018년부터 2030년까지 시장 규모와 예측 및 동향 분석
• 신경혈관 질환
• 심혈관질환
• 정형외과와 MSK 장애
• 종양학
• 안과
• 신장학
• 기타 치료 분야

제6장 임상시험 이미징 시장 : 서비스별 추정·동향 분석

• 부문 대시보드
• 임상시험 이미징 시장 : 서비스 변동 분석
• 임상시험 이미징 시장 서비스 전망
• 2018년부터 2030년까지 시장 규모와 예측 및 동향 분석
• 임상시험 설계와 컨설팅 서비스
• 리딩 및 분석 서비스
• 운영 이미징 서비스
• 시스템 및 테크놀러지 서포트 서비스
• 프로젝트와 데이터 관리

제7장 임상시험 이미징 시장 : 최종 용도별 추정·동향 분석

• 부문 대시보드
• 임상시험 이미징 시장 : 최종 용도 변동 분석
• 임상시험 이미징 시장 최종 용도별 전망
• 2018년부터 2030년까지 시장 규모와 예측 및 동향 분석
• 바이오테크놀러지 및 제약 기업
• 의료기기 제조업체
• 학술기관 및 정부 연구기관
• 수탁연구기관(CRO)
• 기타 최종사용자

제8장 임상시험 이미징 시장 : 지역별 추정·동향 분석

• 지역별 시장 점유율 분석, 2024년 및 2030년
• 지역 시장 대시보드
• 세계 지역 시장 현황
• 시장 규모, 예측 동향 분석, 2018년에서 2030년 :
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제9장 경쟁 구도

• 주요 시장 진출 기업의 최근 동향과 영향 분석
• 벤더 상황
  • 주요 판매대리점 및 채널 파트너 리스트
  • 주요 고객
  • 주요 기업의 시장 점유율 분석, 2024년
  • IXICO plc
  • Navitas Life Sciences
  • Resonance Health
  • ProScan Imaging
  • Radiant Sage LLC
  • Medpace
  • Biomedical Systems Corp.
  • Cardiovascular Imaging Technologies
  • Intrinsic Imaging
  • BioTelemetry

ksm

영문 목차

영문목차

Clinical Trial Imaging Market Growth & Trends:

The global clinical trial imaging market size is expected to reach USD 1.91 billion by 2030, registering a CAGR of 7.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing research and development spending to discover new drugs and therapies to treat chronic diseases is propelling the industry growth. Images obtained from the internal examination of the body are used to determine drug activity. Clinical trial imaging provides rapid, detailed, and accurate screening. The need for clinical trial imaging is rapidly increasing in all phases of trials. Medical imaging in clinical trials is used as a primary, quantitative, and surrogate biomarker.

The clinical trial design includes selecting patient population, stratification based on biomarkers, different methods for allocation treatments, choosing efficient and reliable endpoints and validation of surrogate endpoints, calculating sample size, trial simulations, adaptive trial set-up, statistical and interim analysis, and assisting clients to deal with regulatory authorities such as EMA and FDA to discuss study design or defend study results.

Market players provide analytical testing services, pharmacokinetic, reading, and pharmacodynamics services for enhanced clinical development. IXICO offers advanced technologies for catalyzing clinical trials in neuroscience. Imaging biomarkers by the company help in measuring the safety and effectiveness of therapies used for neuro-imaging. Imaging biomarkers are effective in radiological reads. This provides the reading of MRI scans for central neuro to enhance the assessment of ongoing monitoring of drug safety and subject eligibility

Clinical Trial Imaging Market Report Highlights:

• The reading and analytical services segment held the largest market share at 30.95% in 2024 and is expected to grow at a CAGR of 8.4% from 2025 to 2030, highlighting its critical role in ensuring the accuracy and reliability of imaging data in clinical research.
• The biotechnology and pharmaceutical companies segment accounted for the largest share of 28.7% in 2024. The factor attributing to the dominance of this segment is the need to develop new drugs and therapies to cure chronic diseases.
• Oncology segment held the largest market share of 23.63% in 2024. High prevalence of cancer cases and the constant need for new and innovative therapies to treat various types of cancer are expected to fuel the market growth.
• The contract research organizations (CROs) segment is expected to grow significantly with a CAGR of 8.5% over the forecast period, owing to its essential role in developing new drugs and therapies for chronic diseases.
• North America dominated the market with a revenue share of 47.93% in 2024 due to the increasing geriatric population, along with chronic diseases and growing demand for treatment options.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Modality
  • 1.2.2. Therapeutic Area
  • 1.2.3. Services
  • 1.2.4. End Use
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Modality outlook
  • 2.2.2. Therapeutic area outlook
  • 2.2.3. Services outlook
  • 2.2.4. End Use outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Clinical Trial Imaging Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Growing number of pharmaceutical and biotechnological companies
    • 3.2.1.2. Growing number of contract research organization (CRO)
    • 3.2.1.3. Increasing research and development investments
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost of machineries and installations
• 3.3. Clinical Trial Imaging Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Clinical Trial Imaging Market: Modality Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Clinical Trial Imaging Market: Modality Movement Analysis
• 4.3. Clinical Trial Imaging Market by Modality Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 4.5. Computed Tomography Scan
  • 4.5.1. Computed Tomography Scan Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Magnetic Resonance Imaging
  • 4.6.1. Magnetic Resonance Imaging Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. X-Ray
  • 4.7.1. X-Ray Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.8. Ultrasound
  • 4.8.1. Ultrasound Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.9. Optical Coherence Tomography (OCT)
  • 4.9.1. Optical Coherence Tomography (OCT) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.10. Other Modalities
  • 4.10.1. Other Modalities Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Clinical Trial Imaging Market: Therapeutic Area Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Clinical Trial Imaging Market: Therapeutic Area Movement Analysis
• 5.3. Clinical Trial Imaging Market by Therapeutic Area Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Neurovascular Diseases
  • 5.5.1. Neurovascular Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Cardiovascular Diseases
  • 5.6.1. Cardiovascular Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Orthopedics & MSK Disorders
  • 5.7.1. Orthopedics & MSK Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.8. Oncology
  • 5.8.1. Oncology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.9. Ophthalmology
  • 5.9.1. Ophthalmology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.10. Nephrology
  • 5.10.1. Nephrology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.11. Other Therapeutic Areas
  • 5.11.1. Other Therapeutic Areas Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Clinical Trial Imaging Market: Services Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Clinical Trial Imaging Market: Services Movement Analysis
• 6.3. Clinical Trial Imaging Market by Services Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.5. Clinical Trial Design and Consultation Services
  • 6.5.1. Clinical Trial Design and Consultation Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Reading and Analytical Services
  • 6.6.1. Reading and Analytical Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Operational Imaging Services
  • 6.7.1. Operational Imaging Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.8. System and Technology Support Services
  • 6.8.1. System and Technology Support Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.9. Project and Data Management
  • 6.9.1. Project and Data Management Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Clinical Trial Imaging Market: End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Clinical Trial Imaging Market: End Use Movement Analysis
• 7.3. Clinical Trial Imaging Market by End Use Outlook (USD Million)
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 7.5. Biotechnology and Pharmaceutical Companies
  • 7.5.1. Biotechnology and Pharmaceutical Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Medical Devices Manufacturers
  • 7.6.1. Medical Devices Manufacturers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Academic and Government Research Institutes
  • 7.7.1. Academic and Government Research Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. Contract Research Organizations (CROs)
  • 7.8.1. Contract Research Organizations (CROs) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.9. Other End Users
  • 7.9.1. Other End Users Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Clinical Trial Imaging Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2024 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Global Regional Market Snapshot
• 8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.5. North America
  • 8.5.1. U.S.
    • 8.5.1.1. Key country dynamics
    • 8.5.8.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. Canada
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. Mexico
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Europe
  • 8.6.1. UK
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.8.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. Germany
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.3. France
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework/ reimbursement structure
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.4. Italy
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework/ reimbursement structure
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.5. Spain
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework/ reimbursement structure
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.6. Norway
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework/ reimbursement structure
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.7. Sweden
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Regulatory framework/ reimbursement structure
    • 8.6.7.3. Competitive scenario
    • 8.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.8. Denmark
    • 8.6.8.1. Key country dynamics
    • 8.6.8.2. Regulatory framework/ reimbursement structure
    • 8.6.8.3. Competitive scenario
    • 8.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. Asia Pacific
  • 8.7.8. Japan
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. China
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. India
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.4. Australia
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.5. South Korea
    • 8.7.5.1. Key country dynamics
    • 8.7.5.2. Regulatory framework/ reimbursement structure
    • 8.7.5.3. Competitive scenario
    • 8.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.6. Thailand
    • 8.7.6.1. Key country dynamics
    • 8.7.6.2. Regulatory framework/ reimbursement structure
    • 8.7.6.3. Competitive scenario
    • 8.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.8. Latin America
  • 8.8.1. Brazil
    • 8.8.1.1. Key country dynamics
    • 8.8.1.2. Regulatory framework/ reimbursement structure
    • 8.8.1.3. Competitive scenario
    • 8.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.2. Argentina
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework/ reimbursement structure
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.9. Middle East & Africa
  • 8.9.1. South Africa
    • 8.9.1.1. Key country dynamics
    • 8.9.1.2. Regulatory framework/ reimbursement structure
    • 8.9.1.3. Competitive scenario
    • 8.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.2. Saudi Arabia
    • 8.9.2.1. Key country dynamics
    • 8.9.2.2. Regulatory framework/ reimbursement structure
    • 8.9.2.3. Competitive scenario
    • 8.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.3. UAE
    • 8.9.3.1. Key country dynamics
    • 8.9.3.2. Regulatory framework/ reimbursement structure
    • 8.9.3.3. Competitive scenario
    • 8.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.4. Kuwait
    • 8.9.4.1. Key country dynamics
    • 8.9.4.2. Regulatory framework/ reimbursement structure
    • 8.9.4.3. Competitive scenario
    • 8.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.1.1 Company/Competition Categorization
  • 9.1.2. Innovators
• 9.2. Vendor Landscape
  • 9.2.1. List of key distributors and channel partners
  • 9.2.2. Key customers
  • 9.2.3. Key company market share analysis, 2024
  • 9.2.4. IXICO plc
    • 9.2.4.1. Company overview
    • 9.2.4.2. Financial performance
    • 9.2.4.3. Product benchmarking
    • 9.2.4.4. Strategic initiatives
  • 9.2.5. Navitas Life Sciences
    • 9.2.5.1. Company overview
    • 9.2.5.2. Financial performance
    • 9.2.5.3. Product benchmarking
    • 9.2.5.4. Strategic initiatives
  • 9.2.6. Resonance Health
    • 9.2.6.1. Company overview
    • 9.2.6.2. Financial performance
    • 9.2.6.3. Product benchmarking
    • 9.2.6.4. Strategic initiatives
  • 9.2.7. ProScan Imaging
    • 9.2.7.1. Company overview
    • 9.2.7.2. Financial performance
    • 9.2.7.3. Product benchmarking
    • 9.2.7.4. Strategic initiatives
  • 9.2.8. Radiant Sage LLC
    • 9.2.8.1. Company overview
    • 9.2.8.2. Financial performance
    • 9.2.8.3. Product benchmarking
    • 9.2.8.4. Strategic initiatives
  • 9.2.9. Medpace
    • 9.2.9.1. Company overview
    • 9.2.9.2. Financial performance
    • 9.2.9.3. Product benchmarking
    • 9.2.9.4. Strategic initiatives
  • 9.2.10. Biomedical Systems Corp.
    • 9.2.10.1. Company overview
    • 9.2.10.2. Financial performance
    • 9.2.10.3. Product benchmarking
    • 9.2.10.4. Strategic initiatives
  • 9.2.11. Cardiovascular Imaging Technologies
    • 9.2.11.1. Company overview
    • 9.2.11.2. Financial performance
    • 9.2.11.3. Product benchmarking
    • 9.2.11.4. Strategic initiatives
  • 9.2.12. Intrinsic Imaging
    • 9.2.12.1. Company overview
    • 9.2.12.2. Financial performance
    • 9.2.12.3. Product benchmarking
    • 9.2.12.4. Strategic initiatives
  • 9.2.13. BioTelemetry
    • 9.2.13.1. Company overview
    • 9.2.13.2. Financial performance
    • 9.2.13.3. Product benchmarking
    • 9.2.13.4. Strategic initiatives

관련자료